Hudson Bay Capital Management
AZN icon

Hudson Bay Capital Management’s AstraZeneca AZN Stock Holding History

Hudson Bay Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,700
Closed -$691K – 1381
2025
Q1 		$691K Buy
+4,700
New +$680K ﹤0.01% 981
2023
Q3 		– Sell
-126,950
Closed -$18.2M – 799
2023
Q2 		$18.2M Buy
+126,950
New +$18.7M 0.13% 113

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hudson Bay Capital Management's AZN Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 222,437 shares — an estimated $34.1M sold.

Hudson Bay Capital Management first reported a position in AZN in Q2 2014 and held it in 9 quarters. The position peaked at $35.6M in Q2 2014. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • Hudson Bay Capital Management reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 222,437 AstraZeneca shares in Q4 2025, an estimated $34.1M.
  • Hudson Bay Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 9 quarters.
  • Hudson Bay Capital Management's AstraZeneca position peaked at $35.6M in Q2 2014.
  • 1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.